H.C. Wainwright raised the firm’s price target on Oncolytics (ONCY) to $10 from $5 and keeps a Buy rating on the shares. The firm says the company’s “compelling” data in gastrointestinal tumors increase its confidence ahead of the FDA meeting. H.C. Wainwright is increasingly confident that pelareorep is advancing toward “actionable regulatory pathways” across three “high-value” cancer indications.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics Biotech Reports Increased Q3 Loss Amid Rising Expenses
- Is ONCY a Buy, Before Earnings?
- Oncolytics Biotech Forms Advisory Board to Advance GI Cancer Treatment
- Promising Potential of Oncolytics Biotech’s Pelareorep in SCAC: Buy Rating with $5 Price Target
- Oncolytics Biotech Reports Promising Anal Cancer Data with Pelareorep